Vikash Prashar

ORCID: 0000-0002-3722-0774
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cholinesterase and Neurodegenerative Diseases
  • Synthesis and Characterization of Heterocyclic Compounds
  • Quinazolinone synthesis and applications
  • Synthesis and biological activity
  • Hypothalamic control of reproductive hormones
  • Chemical synthesis and alkaloids
  • Alzheimer's disease research and treatments
  • MicroRNA in disease regulation
  • Computational Drug Discovery Methods
  • Ovarian function and disorders
  • Renin-Angiotensin System Studies
  • Sleep and related disorders
  • Natural product bioactivities and synthesis
  • Regulation of Appetite and Obesity
  • Nicotinic Acetylcholine Receptors Study
  • Phytochemicals and Medicinal Plants
  • Birth, Development, and Health
  • Enzyme function and inhibition
  • Plant Reproductive Biology
  • Sphingolipid Metabolism and Signaling
  • Medicinal Plants and Neuroprotection
  • Smart Cities and Technologies
  • RNA Interference and Gene Delivery
  • Congenital heart defects research
  • Biological Research and Disease Studies

Central University of Punjab
2019-2025

University of Central Punjab
2023

Guru Nanak Dev University
2023

Alzheimer's disease (AD), a multifactorial complex neural disorder, is categorized with progressive memory loss and cognitive impairment as main clinical features. The multitarget directed ligand (MTDL) strategy explored for the treatment of diseases such cancer AD. Herein, we report synthesis screening 24 N-propargyl-substituted diphenylpyrimidine derivatives MTDLs against acetylcholine/butyrylcholine esterases monoamine oxidase enzymes. In this series, VP1 showed most potent MAO-B...

10.1021/acschemneuro.2c00132 article EN ACS Chemical Neuroscience 2022-07-07

Twelve 2,4-bis-substituted quinazoline-based compounds were synthesized and screened for antiproliferative tubulin polymerization enhancing potential.

10.1039/d4md00755g article EN RSC Medicinal Chemistry 2025-01-01

A series of morpholine substituted quinazoline derivatives have been synthesized and evaluated for cytotoxic potential against A549, MCF-7 SHSY-5Y cancer cell lines. These compounds were found to be non-toxic HEK293 cells at 25 μM hence display anticancer potential. In these compounds, AK-3 AK-10 displayed significant activity all the three IC50 values 10.38 ± 0.27 μM, 6.44 0.29 9.54 0.15 Similarly, showed 8.55 0.67 3.15 0.23 3.36 SHSY-5Y, respectively. mechanistic studies, it was that...

10.1039/d2md00023g article EN RSC Medicinal Chemistry 2022-01-01

Abstract Alzheimer's disease (AD) is a multifactorial neurological disorder and single target directed drugs have been found ineffective in the retardation or reversal of state. In last few years, multi‐targeting agents are being explored as drug strategy for effective treatment AD. A series ( 4‐(pent‐4‐yn‐1‐yloxy)phenyl)‐2‐phenylpyrimidine derivatives has synthesized evaluated against monoamine oxidase (MAO) acetylcholinesterase (AChE) enzymes. Most compounds were to be potent inhibitors...

10.1002/slct.202002425 article EN ChemistrySelect 2020-07-15

<title>Abstract</title> Ceramide plays an important role in the myelination process; thus, ceramide biosynthetic pathway could be considered a potential target managing multiple sclerosis (MS). Fingolimod, approved drug for MS, is standard modulator of experimental model MS. Ursolic acid (UA) exhibited neuroprotective activity Cuprizone (CPZ)-induced animal However, protective UA yet to established Therefore, objective study was evaluate effect (50, 100, and 200 mg/kg; p.o.) on level...

10.21203/rs.3.rs-4274921/v1 preprint EN cc-by Research Square (Research Square) 2024-04-23

Background and objectivesAlzheimer's disease (AD), an enduring neurodegenerative malady, contributes significantly to dementia cases, with late-onset AD being more common than early-onset AD. Despite extensive research diagnose treat AD, the intricate protein network impedes development of efficacious drugs or targets. This study endeavored identify previously undiscovered genetic reservoirs associated progression, which could be targeted as therapeutic markers.

10.14218/ge.2023.00143 article EN cc-by-nc Gene Expression 2024-06-24

Introduction: Nitric Oxide (NO) is a diatomic free radical gaseous molecule that formed from L-arginine through NOS (Nitric oxide synthase) catalyzed reaction. NO controls vascular tone (hence blood pressure), insulin secretion, airway tone, and peristalsis, involved in angiogenesis (growth of new vessels) development the nervous system. In CNS, an important messenger molecule, which various major functions brain. has been classified into three isoforms, including nNOS (neuronal NOS), eNOS...

10.2174/1875692118666210616165145 article EN Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine 2021-06-17

Background: Nitric oxide synthase (NOS) is an enzyme that catalyzes the synthesis of nitric (NO) from L-arginine. It has three isoforms- (i) neuronal NOS (nNOS or NOS1), which participates in neural transmission; (ii) inducible (iNOS NOS2), produces NO macrophages; and (iii) endothelial (eNOS NOS3) regulates blood pressure. The eNOS mainly expressed vessels a crucial regulator homeostasis. Objective: present study aimed to unravel role different signaling pathways its involvement as...

10.2174/1875692120666230126110252 article EN Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine 2023-01-27

Abstract Reactive astrogliosis (RA) is a complex pathological condition where astrocytes undergo specific biochemical changes to attain hypertrophy and hyperplasia. RA mechanism being observed in various neurodegenerative disorders (ND) such as Alzheimer's disease (AD), Parkinson's Disease (PD) traumatic brain Injury (TBI). Various models have been designed understand the of activation well determine therapeutics reverse or attenuate for major neurological but study hampered due lack...

10.21203/rs.3.rs-3070568/v1 preprint EN cc-by Research Square (Research Square) 2023-06-29
Coming Soon ...